Harvard Bioscience (HBIO) Inventory (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Inventory data on file, last reported at $22.2 million in Q1 2026.

• On a quarterly basis, Inventory fell 2.68% year-over-year to $22.2 million in Q1 2026; TTM through Mar 2026 was $22.2 million, a 2.68% decrease from a year earlier, with the FY2025 full-year figure at $20.8 million, down 10.5% from the prior year.
• Inventory for Q1 2026 stood at $22.2 million, up from $20.8 million in the prior quarter.
• Over the last five years, Inventory for HBIO reached as high as $29.3 million in Q2 2022 and fell as low as $20.8 million in Q4 2025.
• Historically, Inventory has averaged $24.8 million across 5 years, with a median of $25.1 million in 2024.
• Across the five-year window, Inventory grew 26.61% in 2022 and slipped 16.88% in 2025, its largest moves.
• Year by year, Inventory stood at $26.4 million in 2022, then dropped by 6.52% to $24.7 million in 2023, then decreased by 5.95% to $23.2 million in 2024, then fell by 10.5% to $20.8 million in 2025, then increased by 6.73% to $22.2 million in 2026.
• Per Business Quant data, the three most recent Inventory figures were $22.2 million in Q1 2026, $20.8 million in Q4 2025, and $21.6 million in Q3 2025.